This page shows the latest PPMS news and features for those working in and with pharma, biotech and healthcare.
The trial is a first-of-its-kind, open-label, phase 3b study evaluating the effect of Ocrevus in SPMS and PPMS patients. ... For 75% of patients diagnosed with SPMS and PPMS treated with Ocrevus, they showed no evidence of progression (NEP) after one year
The post-hoc analysis of the ORATORIO study also showed that Ocrevus treatment slowed accumulation of atrophied T2-lesion volume (aT2-LV) compared with placebo at 120 weeks in PPMS. ... According to Roche, those living with PPMS experience three to five
The agreement means NICE can now reverse the rejection it announced in November, and Ocrevus(ocrelizumab), will be fully available to patients with primary progressive multiple sclerosis (PPMS) in England, the ... England's contribution to its revenues
and NICE to reach an agreement that will allow the drug to be covered for PPMS. ... We ask that NICE are given the flexibility to consider an indication-specific price for ocrelizumab in PPMS.”.
NICE says no to Ocrevus in primary progressive MS. On Friday NICE announced that it would not recommend Roche; s Ocrevus (ocrelizumab) for treating primary progressive multiple sclerosis (PPMS) in adults. ... Ocrevus is the only drug approved for PPMS,
There are an estimated 96, 000 Europeans with PPMS, a highly-disabling early-onset form of the disease in which there is no relapsing/remitting stage. ... Nevertheless, the charity points out that the EU license means the drug can only be prescribed for
More from news
Approximately 2 fully matching, plus 8 partially matching documents found.
Take Multiple Sclerosis (MS) for example. MS has four different disease manifestations: Relapsing Remitting (RRMS), Secondary Progressive (SPMS), Primary Progressive (PPMS) and Progressive Relapsing (PRMS).
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...